New diabetes clinical trial: Immune Checkpoint Inhibitors(ICPis)-Induced Endocrine Immune-related Adverse Events (irAEs)

Published on: January 09, 2023 at 11:00AM
Conditions:   Immune Checkpoint Inhibitor;   Endocrine Toxicity
Intervention:  
Sponsor:   Nanjing Medical University
Completed
https://ift.tt/jnWqUMx